In this study, the lead acetate (PbAc2) was used to establish a kidney injury model, and different doses of LBP (200, 400, and 600 mg/kg) were administered to mice with lead toxicity to explore the dose–effect relationship of LBP in resisting lead-induced kidney injury. This evidence concerns the gene LBP and urogenital neoplasm.